Literature DB >> 15755601

New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery.

K Dyet1, A Devoy, R McDowell, D Martin.   

Abstract

New Zealand's epidemic of meningococcal disease began in mid 1991. Surveillance of meningococcal disease in New Zealand is based on a combination of disease notification and organism characterisation. Case numbers and population rates rose from 53 (1.5 per 100,000 population) in 1990 to a high of 650 (17.4 per 100,000 population) in 2001. The highest rates of disease occur in Pacific peoples under 20 years but the highest percentages of cases occur in Maori and European New Zealanders. The epidemic has been driven by a strain identified as B:4:P1.7b,4, ST-41/44 complex/Lineage III. The stability of the P1.7b,4 Por A protein has been demonstrated suggesting that the epidemic may be controlled by a strain-specific OMV vaccine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15755601     DOI: 10.1016/j.vaccine.2005.01.050

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Cellular Immune Responses in Humans Induced by Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines Given Separately and in Combination.

Authors:  Fredrik Oftung; Gro Ellen Korsvold; Audun Aase; Lisbeth M Næss
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

2.  Combined administration of serogroup B meningococcal vaccine and conjugated serogroup C meningococcal vaccine is safe and immunogenic in college students.

Authors:  J D Holmes; D Martin; C Ramsay; E Ypma; P Oster
Journal:  Epidemiol Infect       Date:  2007-08-03       Impact factor: 2.451

3.  Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic.

Authors:  Ingeborg S Aaberge; Philipp Oster; Oddveig S Helland; Anne-Cathrine Kristoffersen; Ellen Ypma; E Arne Høiby; Berit Feiring; Hanne Nøkleby
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

4.  Clonal analysis of the serogroup B meningococci causing New Zealand's epidemic.

Authors:  K H Dyet; D R Martin
Journal:  Epidemiol Infect       Date:  2006-04       Impact factor: 2.451

5.  Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants.

Authors:  N Ruijne; R A Lea; J O'Hallahan; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2006-07

6.  The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.

Authors:  D R Martin; N Ruijne; L McCallum; J O'Hallahan; P Oster
Journal:  Clin Vaccine Immunol       Date:  2006-04

7.  Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005.

Authors:  Lee H Harrison; Kathleen A Shutt; Susanna E Schmink; Jane W Marsh; Brian H Harcourt; Xin Wang; Anne M Whitney; David S Stephens; Amanda A Cohn; Nancy E Messonnier; Leonard W Mayer
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

8.  Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens.

Authors:  Jamie Hosking; Kumanan Rasanathan; Florina Chan Mow; Catherine Jackson; Diana Martin; Jane O'Hallahan; Philipp Oster; Ellen Ypma; Stewart Reid; Ingeborg Aaberge; Sue Crengle; Joanna Stewart; Diana Lennon
Journal:  Clin Vaccine Immunol       Date:  2007-09-26

9.  Epidemiological evidence for the role of the hemoglobin receptor, hmbR, in meningococcal virulence.

Authors:  Odile B Harrison; Nicholas J Evans; Jessica M Blair; Holly S Grimes; Colin R Tinsley; Xavier Nassif; Paula Kriz; Roisin Ure; Steve J Gray; Jeremy P Derrick; Martin C J Maiden; Ian M Feavers
Journal:  J Infect Dis       Date:  2009-07-01       Impact factor: 5.226

10.  Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.

Authors:  Synne Sandbu; Berit Feiring; Philipp Oster; Oddveig S Helland; Hilde S W Bakke; Lisbeth M Naess; Audun Aase; Ingeborg S Aaberge; Anne-Cathrine Kristoffersen; Kjersti M Rydland; Sandrine Tilman; Hanne Nøkleby; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2007-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.